Yahoo
NSE - Delayed Quote INR

Ipca Laboratories Limited (IPCALAB.NS)

1,927.80 +1.60 (+0.08%)
At close: October 30 at 3:30:02 PM GMT+5:30
Chart Range Bar
Loading chart for IPCALAB.NS
  • Previous Close 1,926.20
  • Open 1,945.20
  • Bid --
  • Ask --
  • Day's Range 1,921.40 - 1,964.90
  • 52 Week Range 1,268.00 - 2,038.00
  • Volume 253,523
  • Avg. Volume 390,884
  • Market Cap (intraday) 489.091B
  • Beta (5Y Monthly) 0.04
  • PE Ratio (TTM) 37.31
  • EPS (TTM) 51.67
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield 6.00 (0.31%)
  • Ex-Dividend Date Aug 7, 2026
  • 1y Target Est 1,981.72

Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetes, diabetology, emollients/protectives, fever, gastroenterology, haematology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, regenerative, respiratory, rheumatology, and urology. The company also exports its products to Europe, Africa, the Americas, rest of Asia, the Commonwealth of Independent States, and Australasia. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.

www.ipca.com

17,210

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

IPCALAB.NS
36.34%
S&P BSE SENSEX (^BSESN)
12.63%

1-Year Return

IPCALAB.NS
50.09%
S&P BSE SENSEX (^BSESN)
11.78%

3-Year Return

IPCALAB.NS
98.65%
S&P BSE SENSEX (^BSESN)
16.14%

5-Year Return

IPCALAB.NS
83.24%
S&P BSE SENSEX (^BSESN)
25.55%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue 23.88B
Earnings 2.99B
Profit Margin 12.52%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

0
5B
10B
15B
20B
25B
11.0%
12.0%
13.0%

Analyst Insights

View More

Analyst Price Targets

1,731.00 Low
1,981.72 Average
1,927.80 Current
2,230.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    12.94%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    101.26B

  • Net Income Avi to Common (ttm)

    13.1B

  • Diluted EPS (ttm)

    51.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.96B

  • Total Debt/Equity (mrq)

    8.49%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: